Efficacy of Submicron Vaterite-Based Drug Carriers in Mitigating Doxorubicin-Induced Liver Injury.

The efficacy of drug carriers based on submicron vaterite particles in mitigating doxorubicin-induced liver damage was evaluated. The use of alginate-coated vaterite particles significantly reduced hepatic transaminase levels in rats in comparison with the control group, which received doxorubicin encapsulated in PEG-coated carriers. The incorporation of pH-sensitive vaterite carriers enabled stable retention of doxorubicin, thereby minimizing its off-target release and attenuating hepatotoxicity. These findings demonstrate the potential of alginate-coated vaterite particles to reduce the systemic toxicity associated with doxorubicin chemotherapy and highlight their promise as a platform for developing safer, more effective anticancer therapies with improved therapeutic indices.